PURPOSE: In mouse models of prostate cancer, increased epinephrine levels accelerated tumor growth via the beta2-adrenoreceptor/PKA signaling pathway. It is unknown, however, whether men experience increased epinephrine levels sufficient to activate the beta2-adrenoreceptor/PKA pathway in the prostate gland. We measured epinephrine levels in blood samples collected immediately prior to prostate biopsies and measured phosphorylation of S133CREB (PKA site), S112BAD, T202/Y204ERK, and S473 Akt in prostate biopsy tissue samples. METHODS: Tissue samples and 3 ml of blood were obtained from men (n = 20) recruited from the patients scheduled for prostate biopsies. Epinephrine levels were measured by ELISA. Proteins were extracted from biopsied tissue, and protein phosphorylation was measured by Western blotting with phospho-specific antibodies. Pearson and Spearman's rank correlations were analyzed to assess relationships between blood epinephrine levels and phosphorylation of CREB, BAD, AKT, and ERK. RESULTS: Epinephrine levels above 1 nM were detected in 5 of 20 patients. A strong positive correlation was observed between increased epinephrine levels and CREB phosphorylation. In contrast, no correlation was observed between epinephrine levels and phosphorylation of ERK, BAD, or AKT. CONCLUSION: Our results suggest that increased blood epinephrine levels activate the beta2-adrenoreceptor/PKA signaling pathway in human prostate glands. These results will inform future studies to examine whether beta2-selective blockers can inhibit activation of the epinephrine/ADRB2/PKA pathway in prostate tumors of men with increased epinephrine levels and explore the use of beta2-selective blockers as adjuvant therapy for prostate cancer.
PURPOSE: In mouse models of prostate cancer, increased epinephrine levels accelerated tumor growth via the beta2-adrenoreceptor/PKA signaling pathway. It is unknown, however, whether men experience increased epinephrine levels sufficient to activate the beta2-adrenoreceptor/PKA pathway in the prostate gland. We measured epinephrine levels in blood samples collected immediately prior to prostate biopsies and measured phosphorylation of S133CREB (PKA site), S112BAD, T202/Y204ERK, and S473 Akt in prostate biopsy tissue samples. METHODS: Tissue samples and 3 ml of blood were obtained from men (n = 20) recruited from the patients scheduled for prostate biopsies. Epinephrine levels were measured by ELISA. Proteins were extracted from biopsied tissue, and protein phosphorylation was measured by Western blotting with phospho-specific antibodies. Pearson and Spearman's rank correlations were analyzed to assess relationships between blood epinephrine levels and phosphorylation of CREB, BAD, AKT, and ERK. RESULTS:Epinephrine levels above 1 nM were detected in 5 of 20 patients. A strong positive correlation was observed between increased epinephrine levels and CREB phosphorylation. In contrast, no correlation was observed between epinephrine levels and phosphorylation of ERK, BAD, or AKT. CONCLUSION: Our results suggest that increased blood epinephrine levels activate the beta2-adrenoreceptor/PKA signaling pathway in human prostate glands. These results will inform future studies to examine whether beta2-selective blockers can inhibit activation of the epinephrine/ADRB2/PKA pathway in prostate tumors of men with increased epinephrine levels and explore the use of beta2-selective blockers as adjuvant therapy for prostate cancer.
Authors: Konduru S R Sastry; Adrienne Joy Smith; Yelena Karpova; Sandeep Robert Datta; George Kulik Journal: J Biol Chem Date: 2006-05-25 Impact factor: 5.157
Authors: Konduru S R Sastry; Yelena Karpova; Sergey Prokopovich; Adrienne J Smith; Brian Essau; Avynash Gersappe; Jonathan P Carson; Michael J Weber; Thomas C Register; Yong Q Chen; Raymond B Penn; George Kulik Journal: J Biol Chem Date: 2007-03-12 Impact factor: 5.157
Authors: Naja Rod Nielsen; Tage S Kristensen; Zuo-Feng Zhang; Katrine Strandberg-Larsen; Peter Schnohr; Morten Grønbaek Journal: Ann Epidemiol Date: 2007-04-19 Impact factor: 3.797
Authors: Elizabeth A Kasbohm; Rishu Guo; Charles W Yowell; Gargi Bagchi; Patrick Kelly; Puneeta Arora; Patrick J Casey; Yehia Daaka Journal: J Biol Chem Date: 2005-01-14 Impact factor: 5.157
Authors: Daniel Palm; Kerstin Lang; Bernd Niggemann; Theodore L Drell; Kai Masur; Kurt S Zaenker; Frank Entschladen Journal: Int J Cancer Date: 2006-06-01 Impact factor: 7.396
Authors: Lara Traeger; Frank J Penedo; Jeffrey S Gonzalez; Jason R Dahn; Suzanne C Lechner; Neil Schneiderman; Michael H Antoni Journal: J Psychosom Res Date: 2009-05-19 Impact factor: 3.006
Authors: Evangelina Delgado-González; Ana Alicia Sánchez-Tusie; Giapsy Morales; Carmen Aceves; Brenda Anguiano Journal: Mol Med Date: 2016-02-26 Impact factor: 6.354
Authors: Sazzad Hassan; Ashok Pullikuth; Kyle C Nelson; Anabel Flores; Yelena Karpova; Daniele Baiz; Sinan Zhu; Guangchao Sui; Yue Huang; Young A Choi; Ralph D'Agostino; Ashok Hemal; Urs von Holzen; Waldemar Debinski; George Kulik Journal: Mol Cancer Res Date: 2020-09-14 Impact factor: 5.852
Authors: Benjamin Sunkel; Dayong Wu; Zhong Chen; Chiou-Miin Wang; Xiangtao Liu; Zhenqing Ye; Aaron M Horning; Joseph Liu; Devalingam Mahalingam; Horacio Lopez-Nicora; Chun-Lin Lin; Paul J Goodfellow; Steven K Clinton; Victor X Jin; Chun-Liang Chen; Tim H-M Huang; Qianben Wang Journal: Nucleic Acids Res Date: 2016-01-06 Impact factor: 16.971
Authors: Antonio Barquilla; Ilaria Lamberto; Roberta Noberini; Susanne Heynen-Genel; Laurence M Brill; Elena B Pasquale Journal: Mol Biol Cell Date: 2016-07-06 Impact factor: 4.138